title: Evidence that an altered prolactin release is consequent to abnormal ovarian activity in polycystic ovary syndrome.
abstract: OBJECTIVE
  To investigate whether endogenous dopaminergic activity is impaired in polycystic ovary syndrome (PCOS)-affected women and is normalized by medical ovariectomy.
  
  
  METHODS
  Women with PCOS untreated (n = 23) and treated for 3 months with GnRH analogue (GnRH-a) administration (n = 10) and normal cycling young women (n = 23) as controls.
  
  
  METHODS
  Acute blockade of dopaminergic receptors by the IV administration of 5 mg of the dopaminergic receptor blocking agent sulpiride (sulpiride test) was performed 3 to 7 days after the initiation of spontaneous menses in cycling women or medroxyprogesterone acetate-induced menses in PCOS women. In PCOS women treated with GnRH-a administration (goserelin depot, 3.6 mg SC every 28 days), the sulpiride test was repeated 10 to 15 days after the third GnRH-a administration.
  
  
  METHODS
  Basal PRL levels and PRL increase induced by sulpiride.
  
  
  RESULTS
  Basal PRL levels and the PRL response to sulpiride were increased in women with PCOS. In women with PCOS medical ovariectomy induced by GnRH-a administration reversed to normal both basal and sulpiride-stimulated PRL levels.
  
  
  CONCLUSIONS
  In women with PCOS the abnormal regulation of PRL and presumably of hypothalamic neurotransmitters controlling PRL secretion is not a primary alteration but it is likely dependent on abnormal ovarian functionality.
authors.affiliation: Università degli Studi di Cagliari, Italy.
authors.forename: A M
authors.initials: AM
authors.lastname: Paoletti
authors.forename: A
authors.initials: A
authors.lastname: Cagnacci
authors.forename: R
authors.initials: R
authors.lastname: Soldani
authors.forename: M
authors.initials: M
authors.lastname: Orrù
authors.forename: S
authors.initials: S
authors.lastname: Ajossa
authors.forename: G
authors.initials: G
authors.lastname: Pittorra
authors.forename: P
authors.initials: P
authors.lastname: Mulas
authors.forename: G B
authors.initials: GB
authors.lastname: Melis
mesh_terms: D003692:Delayed-Action Preparations; D004298:Dopamine / Q000502:physiology; D018492:Dopamine Antagonists; D004958:Estradiol / Q000097:blood; D005260:Female; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D010053:Ovary / Q000503:physiopathology*; D011085:Polycystic Ovary Syndrome / Q000503:physiopathology*; D011388:Prolactin / Q000378:metabolism*; D013469:Sulpiride
chemical_list: D003692:Delayed-Action Preparations; D018492:Dopamine Antagonists; D017273:Goserelin; D004958:Estradiol; D013469:Sulpiride; D011388:Prolactin; D017258:Medroxyprogesterone Acetate; D004298:Dopamine